AffiliationCancer Inflammation and Immunity Group, CRUK Manchester Institute, The University of Manchester, Manchester, England, UK
MetadataShow full item record
AbstractIn this issue of JEM, Sulciner et al. (https://doi.org/10.1084/jem.20170681) provide evidence that therapy-induced cancer cell death can, paradoxically, stimulate and accelerate the growth of surviving malignant cells by fueling tumor-promoting inflammation. Resolvins, a class of lipid mediators, counteract this effect, representing an attractive target for therapeutic intervention.
CitationResolving the dark side of therapy-driven cancer cell death. 2018, 215(1): 9-11 J Exp Med
JournalThe Journal of Experimental Medicine
- Die another way: Ferroptosis drives tuberculosis pathology.
- Authors: Meunier E, Neyrolles O
- Issue date: 2019 Mar 4
- TAK1ng control: TAK1 restrains NLRP3 activation.
- Authors: Mangan MS, Latz E
- Issue date: 2018 Apr 2
- Resolvins and omega three polyunsaturated fatty acids: Clinical implications in inflammatory diseases and cancer.
- Authors: Moro K, Nagahashi M, Ramanathan R, Takabe K, Wakai T
- Issue date: 2016 Jul 16
- A20 and ABIN-1 team up against intestinal epithelial cell death.
- Authors: Cadwell K
- Issue date: 2018 Jul 2
- Deciphering cancer fibroblasts.
- Authors: Biffi G, Tuveson DA
- Issue date: 2018 Dec 3